Cav1 (caveolin 1, caveolae protein) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Cav1 (caveolin 1, caveolae protein) Mus musculus
Analyze
Symbol: Cav1
Name: caveolin 1, caveolae protein
RGD ID: 1553438
MGI Page MGI
Description: Enables several functions, including enzyme binding activity; oxysterol binding activity; and protein heterodimerization activity. Involved in several processes, including negative regulation of programmed cell death; regulation of gene expression; and regulation of heart contraction. Acts upstream of with a negative effect on lactation. Acts upstream of or within several processes, including blood vessel diameter maintenance; blood vessel morphogenesis; and negative regulation of signal transduction. Located in several cellular components, including acrosomal membrane; caveola; and perinuclear region of cytoplasm. Part of caveolar macromolecular signaling complex. Colocalizes with focal adhesion. Is expressed in several structures, including cardiovascular system; cerebral cortex; lung; paraxial mesenchyme; and tooth. Used to study Alzheimer's disease; breast cancer; and hypertrophic cardiomyopathy. Human ortholog(s) of this gene implicated in several diseases, including breast cancer (multiple); lipodystrophy (multiple); primary open angle glaucoma; primary pulmonary hypertension; and systemic scleroderma (multiple). Orthologous to human CAV1 (caveolin 1).
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: Cav; Cav-1; cave; caveolin, caveolae protein 1; caveolin, caveolae protein, 22 kDa; caveolin-1
RGD Orthologs
Human
Rat
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Orthologs
More Info more info ...
Latest Assembly: GRCm39 - Mouse Genome Assembly GRCm39
Position:
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39617,306,387 - 17,341,323 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl617,306,334 - 17,341,451 (+)EnsemblGRCm39 Ensembl
GRCm38617,306,335 - 17,341,328 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl617,306,335 - 17,341,452 (+)EnsemblGRCm38mm10GRCm38
MGSCv37617,256,370 - 17,291,324 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36617,256,370 - 17,291,324 (+)NCBIMGSCv36mm8
Celera617,378,835 - 17,414,670 (+)NCBICelera
Cytogenetic Map6A2NCBI
cM Map67.73NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
abdominal aortic aneurysm  (IMP)
acoustic neuroma  (ISO)
Acute Lung Injury  (ISO)
Alcoholic Liver Diseases  (ISO)
Alzheimer's disease  (IAGP)
atherosclerosis  (ISO)
atrial fibrillation  (ISO)
basal cell carcinoma  (ISO)
brain ischemia  (ISO)
breast cancer  (IAGP,ISO)
breast carcinoma  (ISO)
Breast Neoplasms  (ISO)
Carcinogenesis  (ISO)
Cardiomegaly  (ISO)
congenital generalized lipodystrophy type 3  (ISO)
cystic fibrosis  (ISO)
Dermal Fibrosis  (IMP)
diabetes mellitus  (ISO)
Diabetic Nephropathies  (ISO)
diabetic neuropathy  (IMP)
diffuse scleroderma  (ISO)
exfoliation syndrome  (ISO)
Experimental Autoimmune Myocarditis  (ISO)
Experimental Autoimmune Neuritis  (ISO)
Experimental Diabetes Mellitus  (ISO)
Experimental Liver Cirrhosis  (ISO)
Experimental Mammary Neoplasms  (IAGP,IEP,ISO)
familial partial lipodystrophy  (ISO)
Familial Partial Lipodystrophy Type 7  (ISO)
genetic disease  (ISO)
Hemorrhage  (ISO)
high grade glioma  (ISO)
Hyperplasia  (IMP)
hypertension  (ISO)
hypertrophic cardiomyopathy  (IAGP)
hypothyroidism  (ISO)
invasive ductal carcinoma  (ISO)
leiomyoma  (ISO)
limited scleroderma  (ISO)
low tension glaucoma  (ISO)
Lung Neoplasms  (ISO)
Lymphatic Metastasis  (ISO)
melanoma  (ISO)
multiple sclerosis  (ISO)
Neoplasm Metastasis  (IMP,ISO)
Nephrogenic Fibrosing Dermopathy  (ISO)
obesity  (ISO)
open-angle glaucoma  (ISO)
osteoarthritis  (ISO)
ovarian carcinoma  (ISO)
Ovarian Neoplasms  (ISO)
pleomorphic xanthoastrocytoma  (ISO)
primary open angle glaucoma  (ISO)
primary pulmonary hypertension  (ISO)
primary pulmonary hypertension 3  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (IAGP,IMP,ISO)
psoriasis  (ISO)
Pulmonary Arterial Hypertension  (ISO)
pulmonary fibrosis  (IMP,ISO)
pulmonary hypertension  (ISO)
Radioulnar Synostosis with Amegakaryocytic Thrombocytopenia 2  (ISO)
renal cell carcinoma  (ISO)
Reperfusion Injury  (ISO)
Sarcopenia  (ISO)
sciatic neuropathy  (ISO)
silicosis  (ISO)
Spinal Cord Injuries  (ISO)
squamous cell carcinoma  (IMP)
Stevens-Johnson syndrome  (ISO)
Stomach Neoplasms  (ISO)
systemic scleroderma  (ISO)
transient cerebral ischemia  (IMP,ISO)
transitional cell carcinoma  (ISO)
urinary bladder cancer  (ISO)
Weight Gain  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-anisomycin  (ISO)
(1->4)-beta-D-glucan  (EXP)
(R,R,R)-alpha-tocopherol  (ISO)
1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane  (ISO)
1,2-dimethylhydrazine  (EXP)
13-HPODE  (ISO)
17beta-estradiol  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (EXP)
2-ethoxyethanol  (ISO)
2-methoxyethanol  (ISO)
22-Hydroxycholesterol  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP,ISO)
3,3',4,4'-tetrachlorobiphenyl  (EXP)
3,3',5,5'-tetrabromobisphenol A  (EXP)
3-isobutyl-1-methyl-7H-xanthine  (EXP)
3-Nitrobenzanthrone  (ISO)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (EXP,ISO)
5-aza-2'-deoxycytidine  (ISO)
5-fluorouracil  (ISO)
6-propyl-2-thiouracil  (ISO)
acetylcholine  (EXP)
acetylsalicylic acid  (ISO)
acrolein  (ISO)
actinomycin D  (ISO)
aflatoxin B1  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
alpha-pinene  (ISO)
alpha-Zearalanol  (ISO)
aminoguanidine  (ISO)
amitrole  (ISO)
ammonium chloride  (ISO)
amphetamine  (ISO)
amphibole asbestos  (ISO)
antirheumatic drug  (ISO)
Aroclor 1254  (EXP)
arsenite(3-)  (EXP,ISO)
arsenous acid  (ISO)
atrazine  (ISO)
benzo[a]pyrene  (EXP,ISO)
benzo[a]pyrene diol epoxide I  (ISO)
benzo[b]fluoranthene  (EXP)
beta-carotene  (ISO)
beta-lapachone  (ISO)
beta-naphthoflavone  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
Bisphenol A diglycidyl ether  (ISO)
Bisphenol B  (ISO)
bisphenol F  (EXP,ISO)
bleomycin A2  (ISO)
butan-1-ol  (ISO)
butyric acid  (ISO)
cadmium atom  (EXP,ISO)
cadmium dichloride  (ISO)
cadmium nitrate  (ISO)
caffeine  (ISO)
calcitriol  (ISO)
calcium atom  (EXP)
calcium(0)  (EXP)
camptothecin  (ISO)
captan  (EXP)
carbamazepine  (ISO)
carbon nanotube  (EXP)
carboxy-PTIO  (ISO)
celecoxib  (ISO)
CGP 52608  (ISO)
chlorohydrocarbon  (ISO)
chloropicrin  (ISO)
cholesterol  (EXP,ISO)
chromium atom  (ISO)
chrysene  (EXP)
ciprofloxacin  (ISO)
cisplatin  (EXP,ISO)
clofibrate  (ISO)
cobalt dichloride  (ISO)
cordycepin  (EXP,ISO)
corosolic acid  (ISO)
coumestrol  (ISO)
crocidolite asbestos  (EXP)
cumene  (EXP)
cycloheximide  (ISO)
cyclosporin A  (ISO)
cylindrospermopsin  (ISO)
cyproconazole  (ISO)
D-glucose  (ISO)
depsipeptide  (ISO)
desferrioxamine B  (ISO)
dexamethasone  (EXP,ISO)
diallyl disulfide  (ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (ISO)
dibutyl phthalate  (ISO)
diethylstilbestrol  (ISO)
dioxygen  (EXP,ISO)
diuron  (ISO)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
equol  (ISO)
ethanol  (EXP,ISO)
ethyl methanesulfonate  (ISO)
fenofibrate  (ISO)
fipronil  (ISO)
folic acid  (EXP)
folpet  (EXP)
formaldehyde  (ISO)
fulvestrant  (ISO)
furan  (ISO)
gefitinib  (ISO)
genistein  (ISO)
geranylgeraniol  (ISO)
glucose  (ISO)
Glutathione ethyl ester  (ISO)
glycidyl methacrylate  (ISO)
hexadecanoic acid  (ISO)
hydrogen peroxide  (EXP,ISO)
inulin  (EXP)
iron atom  (ISO)
iron(0)  (ISO)
iron(2+) sulfate (anhydrous)  (ISO)
isoprenaline  (EXP)
ivermectin  (ISO)
ketoconazole  (ISO)
L-ascorbic acid  (ISO)
lead diacetate  (ISO)
lipopolysaccharide  (EXP,ISO)
lithocholic acid  (ISO)
lysophosphatidylcholine  (ISO)
manganese atom  (EXP)
manganese(0)  (EXP)
mercury dibromide  (ISO)
methamphetamine  (ISO)
methimazole  (ISO)
methotrexate  (ISO)
methoxychlor  (ISO)
methyl beta-cyclodextrin  (EXP,ISO)
methyl methanesulfonate  (ISO)
methylisothiazolinone  (ISO)
methylmercury chloride  (ISO)
mifepristone  (ISO)
miquelianin  (ISO)
monocrotaline  (ISO)
N-[3-(aminomethyl)benzyl]acetamidine  (ISO)
N-acetyl-L-cysteine  (ISO)
N-acetylsphingosine  (ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (EXP,ISO)
N-methyl-D-aspartic acid  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (ISO)
nicotinic acid  (ISO)
nimesulide  (ISO)
nitric oxide  (ISO)
nitrofen  (ISO)
nitroprusside  (ISO)
NS-398  (ISO)
nystatin  (ISO)
octanoic acid  (EXP)
ouabain  (ISO)
oxaliplatin  (ISO)
ozone  (EXP,ISO)
p-menthan-3-ol  (ISO)
paclitaxel  (ISO)
paracetamol  (EXP,ISO)
paraquat  (ISO)
perfluorooctane-1-sulfonic acid  (EXP)
perfluorooctanoic acid  (ISO)
phenethyl isothiocyanate  (ISO)
phenobarbital  (EXP)
phenylephrine  (EXP)
phenylmercury acetate  (ISO)
pioglitazone  (ISO)
pirinixic acid  (EXP,ISO)
piroxicam  (ISO)
poly(I:C)  (ISO)
potassium chloride  (EXP)
pregnenolone 16alpha-carbonitrile  (ISO)
progesterone  (ISO)
quartz  (EXP)
quercetin  (EXP,ISO)
raloxifene  (ISO)
reactive oxygen species  (EXP)
rebaudioside A  (ISO)
resveratrol  (ISO)
rimonabant  (EXP)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
saracatinib  (ISO)
SB 203580  (EXP,ISO)
SB 431542  (ISO)
senecionine  (EXP)
silicon dioxide  (EXP,ISO)
simvastatin  (EXP,ISO)
sodium arsenite  (EXP,ISO)
Soman  (ISO)
streptozocin  (ISO)
sulfasalazine  (EXP)
tamoxifen  (ISO)
taurocholic acid  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (ISO)
tetrachloromethane  (EXP)
tetraphene  (EXP)
theophylline  (ISO)
thioacetamide  (ISO)
thiram  (ISO)
titanium dioxide  (EXP,ISO)
tolfenamic acid  (ISO)
toluene 2,4-diisocyanate  (EXP,ISO)
topotecan  (ISO)
tremolite asbestos  (EXP)
triadimefon  (ISO)
trichostatin A  (ISO)
triclosan  (ISO)
trimellitic anhydride  (EXP)
Triptolide  (ISO)
troglitazone  (ISO)
trovafloxacin  (EXP)
tyrphostin AG 1478  (ISO)
valproic acid  (ISO)
vinclozolin  (ISO)
vitamin E  (EXP,ISO)
vorinostat  (ISO)
wogonin  (ISO)
wortmannin  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
angiogenesis  (IGI)
angiotensin-activated signaling pathway  (IGI)
animal organ regeneration  (ISO)
apoptotic signaling pathway  (IEA,ISO)
basement membrane organization  (IMP)
calcium ion homeostasis  (IMP)
calcium ion transport  (IMP)
canonical Wnt signaling pathway  (IEA,ISO)
caveola assembly  (IBA,IDA,IGI,IMP,ISO)
caveolin-mediated endocytosis  (IMP,ISO)
cell differentiation  (IBA)
cell population proliferation  (IMP)
cellular response to exogenous dsRNA  (IEA,ISO)
cellular response to hyperoxia  (IEA,ISO)
cellular response to hypoxia  (ISO)
cellular response to mechanical stimulus  (ISO)
cellular response to misfolded protein  (ISO)
cellular response to peptide hormone stimulus  (IGI)
cellular response to starvation  (ISO)
cellular response to transforming growth factor beta stimulus  (IMP)
cellular senescence  (ISO)
cholesterol efflux  (ISO)
cholesterol homeostasis  (IMP)
cytokine-mediated signaling pathway  (IMP)
endocytosis  (TAS)
endothelial cell proliferation  (IMP)
establishment of localization in cell  (IMP)
fibroblast proliferation  (IMP)
glandular epithelial cell differentiation  (IMP)
insulin receptor internalization  (IMP)
intracellular calcium ion homeostasis  (IMP,ISO)
intracellular nitric oxide homeostasis  (IMP)
lactation  (IMP)
lipid storage  (IMP)
maintenance of protein location in cell  (ISO)
mammary gland development  (IMP)
mammary gland involution  (IMP)
MAPK cascade  (IMP)
membrane depolarization  (IMP)
microtubule polymerization  (ISO)
muscle cell cellular homeostasis  (IMP)
negative regulation of anoikis  (IMP,ISO)
negative regulation of BMP signaling pathway  (ISO)
negative regulation of calcium ion import across plasma membrane  (ISO)
negative regulation of canonical Wnt signaling pathway  (IDA)
negative regulation of cation channel activity  (ISO)
negative regulation of cell population proliferation  (IMP)
negative regulation of cytokine-mediated signaling pathway  (IMP)
negative regulation of endothelial cell proliferation  (IBA,IMP,ISO)
negative regulation of epithelial cell differentiation  (IMP)
negative regulation of ERK1 and ERK2 cascade  (ISO)
negative regulation of fibroblast proliferation  (IMP)
negative regulation of inward rectifier potassium channel activity  (IEA,ISO)
negative regulation of MAP kinase activity  (IMP)
negative regulation of MAPK cascade  (IMP)
negative regulation of muscle cell apoptotic process  (ISO)
negative regulation of necroptotic process  (IMP)
negative regulation of neuron differentiation  (ISO)
negative regulation of nitric oxide biosynthetic process  (IMP)
negative regulation of nitric-oxide synthase activity  (IMP)
negative regulation of peptidyl-serine phosphorylation  (ISO)
negative regulation of peptidyl-tyrosine autophosphorylation  (IEA,ISO)
negative regulation of pinocytosis  (ISO)
negative regulation of potassium ion transmembrane transport  (ISO)
negative regulation of protein tyrosine kinase activity  (IEA,ISO)
negative regulation of protein ubiquitination  (IMP,ISO)
negative regulation of receptor signaling pathway via JAK-STAT  (IDA,IGI,IMP)
negative regulation of signal transduction  (IDA)
negative regulation of smooth muscle cell migration  (ISO)
negative regulation of smooth muscle cell proliferation  (ISO)
negative regulation of transcription by RNA polymerase II  (IDA)
negative regulation of tyrosine phosphorylation of STAT protein  (IDA,IMP)
negative regulation of vascular associated smooth muscle cell proliferation  (ISO)
nitric oxide biosynthetic process  (IMP)
positive regulation of calcium ion transport into cytosol  (IDA)
positive regulation of canonical NF-kappaB signal transduction  (IEA,ISO)
positive regulation of catalytic activity  (IMP)
positive regulation of cell adhesion molecule production  (IEA,ISO)
positive regulation of cell migration  (IEA,ISO)
positive regulation of cholesterol efflux  (IEA,ISO)
positive regulation of cold-induced thermogenesis  (IMP)
positive regulation of endocytosis  (ISO)
positive regulation of endothelial cell proliferation  (ISO)
positive regulation of ERAD pathway  (IEA,ISO)
positive regulation of extrinsic apoptotic signaling pathway  (IEA,ISO)
positive regulation of gap junction assembly  (IMP)
positive regulation of gene expression  (IMP)
positive regulation of intrinsic apoptotic signaling pathway  (IEA,ISO)
positive regulation of microtubule polymerization  (ISO)
positive regulation of peptidyl-serine phosphorylation  (IEA,ISO)
positive regulation of protein ubiquitination  (ISO)
positive regulation of signal transduction  (ISO)
positive regulation of toll-like receptor 3 signaling pathway  (IEA,ISO)
positive regulation of vasoconstriction  (IMP,ISO)
post-transcriptional regulation of gene expression  (IMP)
protein localization  (IMP)
protein localization to basolateral plasma membrane  (ISO)
protein localization to plasma membrane raft  (ISO)
protein transport  (IMP)
receptor internalization  (ISO,ISS)
receptor-mediated endocytosis of virus by host cell  (IEA,ISO)
regulation of blood coagulation  (IEA,ISO)
regulation of cell communication by electrical coupling involved in cardiac conduction  (IMP)
regulation of cytosolic calcium ion concentration  (IBA,IEA,ISO)
regulation of entry of bacterium into host cell  (ISO)
regulation of fatty acid metabolic process  (IMP)
regulation of heart rate by cardiac conduction  (IMP)
regulation of membrane repolarization during action potential  (IEA,ISO)
regulation of peptidase activity  (IMP)
regulation of ruffle assembly  (ISO)
regulation of smooth muscle contraction  (IMP)
regulation of the force of heart contraction  (IMP)
regulation of the force of heart contraction by chemical signal  (IGI)
regulation of ventricular cardiac muscle cell action potential  (IMP)
response to bacterium  (IEA,ISO)
response to calcium ion  (IDA)
response to estrogen  (IDA,ISO)
response to gamma radiation  (ISO)
response to glucocorticoid  (ISO)
response to hypoxia  (IMP)
response to ischemia  (IMP)
response to mechanical stimulus  (ISO)
response to nutrient  (ISO)
response to progesterone  (ISO)
response to xenobiotic stimulus  (ISO)
skeletal muscle tissue development  (IMP)
T cell costimulation  (ISO,ISS)
triglyceride metabolic process  (IMP)
tyrosine phosphorylation of STAT protein  (IMP)
vasculogenesis  (IMP)
vasoconstriction  (IMP)
vesicle organization  (ISO)

Cellular Component

Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
abnormal actin cytoskeleton morphology  (IAGP)
abnormal adipose tissue physiology  (IAGP)
abnormal astrocyte morphology  (IAGP)
abnormal blood homeostasis  (IAGP)
abnormal bone mineralization  (IAGP)
abnormal bone trabecula morphology  (IAGP)
abnormal brain internal capsule morphology  (IAGP)
abnormal brain vasculature morphology  (IAGP)
abnormal branching of the mammary ductal tree  (IAGP)
abnormal brown fat cell morphology  (IAGP)
abnormal cell cycle  (IAGP)
abnormal cell cytoskeleton morphology  (IAGP)
abnormal cell morphology  (IAGP)
abnormal cellular cholesterol metabolism  (IAGP)
abnormal cellular respiration  (IAGP)
abnormal chemokine secretion  (IAGP)
abnormal chondrocyte physiology  (IAGP)
abnormal circulating amino acid level  (IAGP)
abnormal circulating free fatty acids level  (IAGP)
abnormal CNS glial cell morphology  (IAGP)
abnormal compact bone morphology  (IAGP)
abnormal costochondral joint morphology  (IAGP)
abnormal cytokine level  (IAGP)
abnormal dendrite morphology  (IAGP)
abnormal dentate gyrus morphology  (IAGP)
abnormal digestive system physiology  (IAGP)
abnormal fat cell morphology  (IAGP)
abnormal fibroblast chemotaxis  (IAGP)
abnormal free fatty acids level  (IAGP)
abnormal gait  (IAGP)
abnormal glucose homeostasis  (IAGP)
abnormal gonadal fat pad morphology  (IAGP)
abnormal hippocampus CA1 region morphology  (IAGP)
abnormal homeostasis  (IAGP)
abnormal hyaline cartilage morphology  (IAGP)
abnormal involuntary movement  (IAGP)
abnormal lactation  (IAGP)
abnormal lipid homeostasis  (IAGP)
abnormal lipid level  (IAGP)
abnormal liver physiology  (IAGP)
abnormal locomotor behavior  (IAGP)
abnormal long bone epiphyseal plate morphology  (IAGP)
abnormal long bone epiphyseal plate proliferative zone  (IAGP)
abnormal long bone epiphysis morphology  (IAGP)
abnormal long bone hypertrophic chondrocyte zone  (IAGP)
abnormal long bone metaphysis morphology  (IAGP)
abnormal lung morphology  (IAGP)
abnormal lung vasculature morphology  (IAGP)
abnormal macrophage physiology  (IAGP)
abnormal mammary fat pad morphology  (IAGP)
abnormal mammary gland duct morphology  (IAGP)
abnormal mammary gland epithelium morphology  (IAGP)
abnormal mammary gland growth during pregnancy  (IAGP)
abnormal mammary gland morphology  (IAGP)
abnormal microtubule organizing center morphology  (IAGP)
abnormal myocardial fiber morphology  (IAGP)
abnormal myocardium layer morphology  (IAGP)
abnormal neutrophil physiology  (IAGP)
abnormal nitric oxide homeostasis  (IAGP)
abnormal osteoclast morphology  (IAGP)
abnormal pulmonary alveolar parenchyma morphology  (IAGP)
abnormal pulmonary elastic fiber morphology  (IAGP)
abnormal pulmonary endothelial cell surface  (IAGP)
abnormal renal calcium reabsorption  (IAGP)
abnormal respiratory electron transport chain  (IAGP)
abnormal respiratory mechanics  (IAGP)
abnormal respiratory quotient  (IAGP)
abnormal skeletal muscle fiber morphology  (IAGP)
abnormal skeletal muscle morphology  (IAGP)
abnormal thyroid follicular cell morphology  (IAGP)
abnormal trabecular bone morphology  (IAGP)
abnormal triglyceride level  (IAGP)
abnormal type II pneumocyte morphology  (IAGP)
abnormal uterus physiology  (IAGP)
abnormal vascular endothelial cell morphology  (IAGP)
abnormal vascular wound healing  (IAGP)
abnormal vasoconstriction  (IAGP)
abnormal vasodilation  (IAGP)
abnormal vesicle-mediated transport  (IAGP)
absent caveolae  (IAGP)
absent subcutaneous adipose tissue  (IAGP)
amyloid beta deposits  (IAGP)
astrocytosis  (IAGP)
brain ischemia  (IAGP)
cardiac fibrosis  (IAGP)
cardiac hypertrophy  (IAGP)
cardiac interstitial fibrosis  (IAGP)
cardiomyopathy  (IAGP)
congestive heart failure  (IAGP)
decreased body weight  (IAGP)
decreased brain size  (IAGP)
decreased brain weight  (IAGP)
decreased cardiac muscle contractility  (IAGP)
decreased circulating adiponectin level  (IAGP)
decreased circulating glucose level  (IAGP)
decreased circulating glycerol level  (IAGP)
decreased circulating leptin level  (IAGP)
decreased CNS synapse formation  (IAGP)
decreased core body temperature  (IAGP)
decreased exploration in new environment  (IAGP)
decreased fatty acids level  (IAGP)
decreased fibroblast chemotaxis  (IAGP)
decreased grip strength  (IAGP)
decreased heart left ventricle muscle contractility  (IAGP)
decreased heart left ventricle posterior wall thickness  (IAGP)
decreased heart ventricle muscle contractility  (IAGP)
decreased hepatocyte proliferation  (IAGP)
decreased liver glycogen level  (IAGP)
decreased liver triglyceride level  (IAGP)
decreased locomotor activity  (IAGP)
decreased lung compliance  (IAGP)
decreased subcutaneous adipose tissue amount  (IAGP)
decreased susceptibility to atherosclerosis  (IAGP)
decreased susceptibility to diet-induced hepatic steatosis  (IAGP)
decreased susceptibility to diet-induced obesity  (IAGP)
decreased susceptibility to endotoxin shock  (IAGP)
decreased total body fat amount  (IAGP)
decreased tumor incidence  (IAGP)
decreased vasoconstriction  (IAGP)
decreased white adipose tissue amount  (IAGP)
decreased white fat cell lipid droplet size  (IAGP)
dilated cardiomyopathy  (IAGP)
dilated heart left ventricle  (IAGP)
dilated heart right ventricle  (IAGP)
enhanced gluconeogenesis  (IAGP)
enhanced lipolysis  (IAGP)
enlarged endometrial glands  (IAGP)
epidermal hyperplasia  (IAGP)
heart inflammation  (IAGP)
heart left ventricle hypertrophy  (IAGP)
heart right ventricle hypertrophy  (IAGP)
hippocampal neuron degeneration  (IAGP)
hyperglycemia  (IAGP)
impaired adaptive thermogenesis  (IAGP)
impaired exercise endurance  (IAGP)
impaired lipolysis  (IAGP)
impaired liver regeneration  (IAGP)
impaired neutrophil recruitment  (IAGP)
impaired wound healing  (IAGP)
increased airway resistance  (IAGP)
increased blood urea nitrogen level  (IAGP)
increased bone strength  (IAGP)
increased bone trabecula number  (IAGP)
increased brown adipose tissue amount  (IAGP)
increased brown fat cell lipid droplet size  (IAGP)
increased cerebral infarct size  (IAGP)
increased circulating cholesterol level  (IAGP)
increased circulating CXCL10 level  (IAGP)
increased circulating glycerol level  (IAGP)
increased circulating HDL cholesterol level  (IEA)
increased circulating insulin level  (IAGP)
increased circulating interferon-gamma level  (IAGP)
increased circulating interleukin-6 level  (IAGP)
increased circulating LDL cholesterol level  (IAGP)
increased circulating triglyceride level  (IAGP)
increased circulating tumor necrosis factor level  (IAGP)
increased circulating VLDL cholesterol level  (IAGP)
increased circulating VLDL triglyceride level  (IAGP)
increased endometrial gland number  (IAGP)
increased femoral compact bone area  (IAGP)
increased fibroblast proliferation  (IAGP)
increased food intake  (IAGP)
increased heart left ventricle wall thickness  (IAGP)
increased heart left ventricle weight  (IAGP)
increased heart rate  (IEA)
increased heart right ventricle muscle contractility  (IAGP)
increased heart right ventricle wall thickness  (IAGP)
increased heart weight  (IAGP)
increased hemoglobin content  (IEA)
increased incidence of tumors by chemical induction  (IAGP)
increased kidney weight  (IAGP)
increased liver glycogen level  (IAGP)
increased liver weight  (IAGP)
increased long bone epiphyseal plate size  (IAGP)
increased lung elastance  (IAGP)
increased lung endothelial cell proliferation  (IAGP)
increased mammary gland tumor incidence  (IAGP)
increased mean corpuscular hemoglobin  (IEA)
increased mean corpuscular volume  (IEA)
increased oxygen consumption  (IAGP)
increased respiratory quotient  (IAGP)
increased susceptibility to bacterial infection  (IAGP)
increased susceptibility to bacterial infection induced morbidity/mortality  (IAGP)
increased susceptibility to induced morbidity/mortality  (IAGP)
increased systemic arterial blood pressure  (IAGP)
increased trabecular bone thickness  (IAGP)
increased triglyceride level  (IAGP)
increased urine calcium level  (IAGP)
increased vascular permeability  (IAGP)
increased vasodilation  (IAGP)
insulin resistance  (IAGP)
limb grasping  (IAGP)
lung inflammation  (IAGP)
mammary gland duct hyperplasia  (IAGP)
mammary gland hyperplasia  (IAGP)
myocardial fiber disarray  (IAGP)
ovary cyst  (IAGP)
premature bone ossification  (IAGP)
premature death  (IAGP)
pulmonary edema  (IAGP)
pulmonary hyperemia  (IAGP)
pulmonary hypertension  (IAGP)
pulmonary interstitial fibrosis  (IAGP)
reduced fertility  (IAGP)
short stride length  (IAGP)
slow postnatal weight gain  (IAGP)
tau protein deposits  (IAGP)
thick interventricular septum  (IAGP)
thick pulmonary interalveolar septum  (IAGP)
thin interventricular septum  (IAGP)
urolithiasis  (IAGP)
uterus cyst  (IAGP)
weight loss  (IAGP)
References

References - curated
# Reference Title Reference Citation
1. Global gene expression profiling and tissue microarray reveal novel candidate genes and down-regulation of the tumor suppressor gene CAV1 in sporadic vestibular schwannomas. Aarhus M, etal., Neurosurgery. 2010 Oct;67(4):998-1019; discussion 1019. doi: 10.1227/NEU.0b013e3181ec7b71.
2. Lack of association of SNP rs4236601 near CAV1 and CAV2 with POAG in a Saudi cohort. Abu-Amero KK, etal., Mol Vis. 2012;18:1960-5. Epub 2012 Jul 18.
3. Increased expression of caveolin-1 and -2 in the hearts of Lewis rats with experimental autoimmune myocarditis. Ahn M, etal., Autoimmunity. 2006 Sep;39(6):489-95.
4. Contribution of caveolin-1 to ventricular nitric oxide in age-related adaptation to hypovolemic state. Arreche ND, etal., Regul Pept. 2012 Nov 10;179(1-3):43-9. doi: 10.1016/j.regpep.2012.08.002. Epub 2012 Sep 3.
5. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Bagnoli M, etal., Oncogene. 2000 Sep 28;19(41):4754-63.
6. Opposite pattern of MDR1 and caveolin-1 gene expression in human atherosclerotic lesions and proliferating human smooth muscle cells. Batetta B, etal., Cell Mol Life Sci. 2001 Jul;58(8):1113-20.
7. Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in rats. Bi LQ, etal., Int Immunopharmacol. 2013 May;16(1):7-16. doi: 10.1016/j.intimp.2013.03.010. Epub 2013 Mar 26.
8. EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Bruckner K, etal., Neuron 1999 Mar;22(3):511-24.
9. Downregulation and altered spatial pattern of caveolin-1 in chronic plaque psoriasis. Campbell L, etal., Br J Dermatol. 2002 Oct;147(4):701-9.
10. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers. Chen ST, etal., Int J Mol Med. 2004 Oct;14(4):577-82.
11. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Cui J, etal., Prostate. 2001 Feb 15;46(3):249-56.
12. Catabolic stress induces features of chondrocyte senescence through overexpression of caveolin 1: possible involvement of caveolin 1-induced down-regulation of articular chondrocytes in the pathogenesis of osteoarthritis. Dai SM, etal., Arthritis Rheum. 2006 Mar;54(3):818-31.
13. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Del Galdo F, etal., Arthritis Rheum. 2008 Sep;58(9):2854-65. doi: 10.1002/art.23791.
14. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Di Vizio D, etal., Cancer Biol Ther. 2007 Aug;6(8):1263-8. Epub 2007 May 17.
15. Peripheral nerve injury alters blood-spinal cord barrier functional and molecular integrity through a selective inflammatory pathway. Echeverry S, etal., J Neurosci. 2011 Jul 27;31(30):10819-28.
16. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. Engelman JA, etal., J Biol Chem. 1998 Aug 7;273(32):20448-55.
17. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Fong A, etal., Am J Clin Pathol. 2003 Jul;120(1):93-100.
18. Up-regulation of caveolin-1 by DJ-1 attenuates rat pulmonary arterial hypertension by inhibiting TGFβ/Smad signaling pathway. Gao W, etal., Exp Cell Res. 2017 Dec 1;361(1):192-198. doi: 10.1016/j.yexcr.2017.10.019. Epub 2017 Oct 22.
19. Vascular microarray profiling in two models of hypertension identifies Cav-1, Rgs2 and Rgs5 as antihypertensive targets. Grayson TH, etal., BMC Genomics. 2007 Nov 7;8(1):404.
20. Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and reperfusion injury. Gu Y, etal., J Neurochem. 2012 Jan;120(1):147-56. doi: 10.1111/j.1471-4159.2011.07542.x. Epub 2011 Nov 17.
21. Association of a CAV-1 haplotype to familial aggressive prostate cancer. Haeusler J, etal., Prostate. 2005 Oct 1;65(2):171-7.
22. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Hayashi K, etal., Cancer Res. 2001 Mar 15;61(6):2361-4.
23. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. Horiguchi A, etal., J Urol. 2004 Aug;172(2):718-22.
24. Dietary obesity increases NO and inhibits BKCa-mediated, endothelium-dependent dilation in rat cremaster muscle artery: association with caveolins and caveolae. Howitt L, etal., Am J Physiol Heart Circ Physiol. 2012 Jun;302(12):H2464-76. Epub 2012 Apr 6.
25. Caveolin-1 deficiency increases cerebral ischemic injury. Jasmin JF, etal., Circ Res. 2007 Mar 16;100(5):721-9. Epub 2007 Feb 9.
26. Association study of genetic variants on chromosome 7q31 with susceptibility to normal tension glaucoma in a Japanese population. Kato T, etal., Eye (Lond). 2013 Aug;27(8):979-83. doi: 10.1038/eye.2013.123. Epub 2013 Jun 7.
27. Functional annotation of a full-length mouse cDNA collection. Kawai J, etal., Nature. 2001 Feb 8;409(6821):685-90.
28. Increased phosphorylation of caveolin-1 in the sciatic nerves of Lewis rats with experimental autoimmune neuritis.